The integration of multi-omics data offers a promising conceptual lens through which to understand the intricate immune-neuronal interactions driving AE, though substantial challenges in data standardization, clinical validation, and implementation remain to be addressed.
Abstract
Autoimmune encephalitis (AE) represents a heterogeneous group of disorders characterized by immune-mediated attacks on neuronal antigens within the central nervous system (CNS), leading to diverse clinical manifestations and posing significant challenges in diagnosis and treatment. Recent advances in multi-omics technologies—including genomics, transcriptomics, proteomics, metabolomics, and immunomics—are beginning to provide unprecedented opportunities to unravel the complex immunopathophysiology of AE at a systems level. This review critically examines the application of integrated multi-omics approaches in AE research, with particular emphasis on immunological mechanisms underlying disease pathogenesis. We focus on: (i) the identification of potential diagnostic and prognostic biomarkers with rigorous validation frameworks; (ii) the elucidation of molecular heterogeneity underlying clinical variability, including B-cell clonal expansion, small-cohort evidence for T follicular helper (Tfh) expansion with inferred T follicular regulatory (Tfr) imbalance, and cytotoxic CD8+ T-cell-mediated neuronal injury in paraneoplastic/intracellular-antigen contexts; (iii) the conceptual development of precision medicine strategies tailored to individual immunophenotypic profiles; and (iv) the critical appraisal of current evidence quality and methodological limitations. By synthesizing current findings, this article aims to establish a comprehensive immunological framework that supports the future advancement of personalized therapeutic interventions. The integration of multi-omics data offers a promising conceptual lens through which to understand the intricate immune-neuronal interactions driving AE, though substantial challenges in data standardization, clinical validation, and implementation remain to be addressed.
Current evidence on advances in clinical research and immunotherapy across the major autoimmune CNS disease groups is synthesized, with a particular focus on trial designs, endpoints, and the evolution from observational cohorts to randomized controlled trials.
This study interrogated human plasma samples from AID patients and age- and sex-matched healthy controls for biomarker signatures and identified three inflammatory clusters among the analyzed patient samples indicating the underlying AID endotypes.
Dennis Özcelik, Julian J. Albers, Stéphanie Delmas et al.· Journal of Immunology· 0 citations
This review synthesizes advances in neuroimmunology, clinical phenotyping, diagnostics, immunomodulatory and antiseizure therapies, neuromodulation, and patient and family centered outcomes, and outlines future directions focused on biomarker-driven precision medicine, disease-modifying strategies, and interdisciplinar...
Alica M. Goldman, Nora Wong, A. Vezzani et al.· Epilepsy Currents· 0 citations
This review synthesises current insights into MS immunopathology and recent advances in B-cell-targeted therapies and CAR-T approaches, highlighting an evolving therapeutic landscape focused on improving disease control and long-term outcomes.
Julia Lewtak, Kamil Syga, A. Jamróz-Wiśniewska et al.· Journal of Medical Sciences· 0 citations
Key findings from multi-omics studies in uveitis are summarized, the sample sources and analytical strategies employed are described, and the transformative potential of integrative omics in precision ophthalmology is highlighted.
Cheng-Zhi Liu, Qiong Wu, M. Yuan et al.· International Journal of Mol...· 0 citations
IFIT1 and IFIT3 represent promising biomarkers for diagnosing SLE and appear to mediate key immune and metabolic disturbances and serve as an accurate and reliable instrument for early diagnosis and personalized therapy.
Luofei Huang, Jian Shi· Clinical and Experimental Me...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.